The study involved 110 volunteers aged 18-59, 13 of whom had previously suffered from COVID-19. The trials were conducted without placebo control, and all participants received the drug.
“Most of the adverse reactions were mild (66.4% of all vaccinated), some were moderate (5.5%). No serious adverse events have been identified, ”wrote the authors of the article.
The results of clinical trials have shown that the vaccine forms strong humoral and cellular immunity both among those who have not been previously infected and among those who have recovered from COVID-19. At the same time, in the seropositive group (with already existing antibodies to coronavirus), the immune response was developed faster.
Previously, the center them. Gamalei announced the results of clinical trials of “Sputnik Light” with the participation of 28 thousand people in Moscow, reports RDIF. When used alone, the effectiveness of the drug was 70% against the delta variant of the coronavirus within three months after vaccination. Among volunteers under 60 years of age, the effectiveness exceeded 75%.
When using the drug for revaccination (booster) after two doses of Sputnik V, Sputnik-Light reduced the risk of contracting the delta variant by more than 83%, and the risk of hospitalization by 94%.